You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Feasibility and proof of concept of a dense, low cost, network of sensors driving Intelligent building Agents for air quality and energy control.

    SBC: XMARK LABS, LLC            Topic: 6

    Commercial buildings use 35% of the entire US energy output, and up to a third of that energy is wasted. Rapidly rising fuel costs, increasing concern about climate change, and policy directives from the Biden Administration are all driving the need for increased energy efficiency and the elimination of waste. At the same time, the COVID-19 pandemic has dramatically increased public awareness of t ...

    SBIR Phase I 2023 Department of CommerceNational Institute of Standards and Technology
  2. Development of a wearable light-based remote monitoring system for early detection of postpartum hemorrhage

    SBC: ARMOR MEDICAL INC.            Topic: CDC

    PROJECT SUMMARY There is an urgent need to develop technologies which address preventable causes of maternal deaths and improve maternal health outcomes. In the United States (US) there exist deeply concerning racial and ethnic disparities in maternal health outcomes (with black mothers experiencing a rt3x higher mortality rate than non- black mothers). Furthermore, the US has the highest maternal ...

    SBIR Phase I 2023 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Army Wire Harness Replacement Activity

    SBC: BASCOM HUNTER TECHNOLOGIES INC            Topic: DLA232001

    The United States Army has requested interest parties submit proposals to become approved suppliers for three wire harness assemblies, part numbers 10033768, 10024853, and 12574943.  The past manufacturers of these products will no longer produce the item. Without a viable supply chain in place, the readiness of the Army could be placed at risk. Bascom Hunter Technologies, Inc has the technical ...

    SBIR Phase I 2023 Department of DefenseDefense Logistics Agency
  4. Advancing next-generation sequencing for optimization of rAAV production

    SBC: BIOINFOEXPERTS LLC            Topic: FDA

    1 BioInfoExperts develops pathogen-associated next-generation sequencing (NGS) analytics and software for a2 growing number of industries that require genome characterization. In the proposed SBIR Phase I project, we3 will develop NGS analytics for the recombinant adeno-associated viruses (rAAVs) manufacturing industry; in4 Phase II, we will incorporate the NGS analytics into a a software-as-a-ser ...

    SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration
  5. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Novel non-narcotic analgesic for acute and chronic pain

    SBC: South Rampart Pharma, LLC            Topic: 106

    PROJECT SUMMARYSouth Rampart Pharma (SRP) is an early clinical-stage company focused on developing SRP-001, a novel non-opioid designed to treat moderate-to-severe acute and chronic pain without the dose-limiting hepatotoxicity of acetaminophen and nephrotoxicity of NSAIDs, and the misuse and addictive potential of opioids. SRP-001 is currently in Phase 1 trials where interim data support the expe ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. GW-TT2, a New Drug Product for Tinnitus.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: PA19272

    Every soldier, Marine, airman, and sailor will be exposed to hazardous noise at some point in his or her career. One major consequence of noise exposure is tinnitus. Tinnitus can impede communication, reduce environmental and social awareness, and degrade combat performance and mission effectiveness. Tinnitus can also harm a service member’s quality of life and future employability with severe f ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government